Jenburkt Pharmaceuticals Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2012
For the nine months, the company's net sales/income from operations was INR 520.8 million compared with INR 440.6 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 64.9 million compared with INR 61.2 million a year ago. Profit from ordinary activities before tax was INR 64.6 million compared with INR 60.1 million a year ago. Net profit was INR 45.4 million or INR 9.77 per basic and diluted share compared with INR 42.6 million or INR 9.17 per basic and diluted share a year ago.